REGULATORY
Drug Pricing, LLP Rule in MHLW’s Draft Supplementary Opinions for FY2024 Reform
The Central Social Insurance Medical Council (Chuikyo) on January 31 discussed a draft of supplementary opinions that will be attached to its recommendation for the FY2024 reimbursement reform. Discussions will continue at its next meeting as well. The draft paper…
To read the full story
Related Article
REGULATORY
- MHLW Publishes Updated LLP List with Higher Surcharges from June
April 8, 2026
- Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
- Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
- Japan Identifies 28 New “Drug Loss” Products from 2021-23 Approvals
April 7, 2026
- Japan OKs Zolgensma Intrathecal Form, Breyanzi Expansion, New EB Therapy
April 6, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…





